Since 2009, a large panel of broad and potent monoclonal neutralizing antibodies (MoNAbs) against HIV-1 have been isolated. These MoNAbs can protect from lllV-1 infection and suppress established infection in animal models. Because their efficacy should be evaluated in human clinical trials, it is of importance to define the sensitivity of the most contemporary transmitted variants to these MoNAbs. We, and others previously, reported that HIV-1 has become more resistant to neutralization over the course of the epidemic (Bunnik et al., Nature Med 2010, Bouvin-Pley et al., PloS Pathog 2013). Methods: Here we extended the analyses to the most potent MoNAbs described since then, either more recently isolated or improved by structure-based ge...
BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals is need...
Since 2009, a large panel of broad and potent monoclonal neutralizing antibodies (MoNAbs) against HI...
Extending our previous analyses to the most recently described broadly neutralizing monoclonal antib...
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antib...
<div><p>We compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients...
For the development of a neutralizing antibody-based human immunodeficiency virus type 1 (HIV-1) vac...
To study how virus evolution affects neutralization sensitivity and to determine changes that occur ...
Background: The rapid and continual viral escape from neutralizing antibodies is well documented in ...
BACKGROUND: The rapid and continual viral escape from neutralizing antibodies is well documented in ...
Monoclonal antibodies that effectively neutralize HIV-1 have been widely sought, yet few have been i...
Background: The rapid and continual viral escape from neutralizing antibodies is well documented in ...
Following infection by HIV-1, the host immune response is unable to clear the virus due to a variet...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals is need...
Since 2009, a large panel of broad and potent monoclonal neutralizing antibodies (MoNAbs) against HI...
Extending our previous analyses to the most recently described broadly neutralizing monoclonal antib...
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antib...
<div><p>We compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients...
For the development of a neutralizing antibody-based human immunodeficiency virus type 1 (HIV-1) vac...
To study how virus evolution affects neutralization sensitivity and to determine changes that occur ...
Background: The rapid and continual viral escape from neutralizing antibodies is well documented in ...
BACKGROUND: The rapid and continual viral escape from neutralizing antibodies is well documented in ...
Monoclonal antibodies that effectively neutralize HIV-1 have been widely sought, yet few have been i...
Background: The rapid and continual viral escape from neutralizing antibodies is well documented in ...
Following infection by HIV-1, the host immune response is unable to clear the virus due to a variet...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals is need...